Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Julide Tok Celebi is active.

Publication


Featured researches published by Julide Tok Celebi.


Journal of Cutaneous Pathology | 2008

Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting

Saurabh Lodha; Sarika Saggar; Julide Tok Celebi; David N. Silvers

Background:  The gold standard for diagnosing melanocytic neoplasms is by histopathologic examination. However, lack of agreement among expert dermatopathologists in evaluating these tumors has been well established in experimental settings.


Journal of Medical Genetics | 2000

Identification of PTEN mutations in metastatic melanoma specimens

Julide Tok Celebi; Igor Shendrik; David N. Silvers; Monica Peacocke

CONTEXT PTEN,a tumour suppressor gene located on chromosome 10q23, develops somatic mutations in various tumours and tumour cell lines including brain, endometrium, prostate, breast, kidney, thyroid, liver, and melanoma. OBJECTIVES To investigate the mutational profile of this gene further, as well as its role in tumour progression in melanoma. DESIGN, SETTINGS We examined 21 metastatic melanoma samples for 10q23 allelic losses andPTEN sequence alterations. Additionally, we screened these samples for mutations inCDKN2A, a gene in which alterations are well documented in primary melanoma as well as in the germline of familial melanoma. RESULTS Loss of heterozygosity (LOH) at 10q23 was observed in 33% (7/21) of the samples tested. We identified four sequence alterations in PTEN(19%) and two in CDKN2A (9.5%). Of interest, only one case showed mutations in both genes. CONCLUSIONS These data support the notion that PTEN alterations occur in some metastatic melanomas, and that mutation of this gene plays a role in the progression of some forms of melanoma.


Journal of Medical Genetics | 2005

Genetics of skin appendage neoplasms and related syndromes

D A Lee; M E Grossman; P Schneiderman; Julide Tok Celebi

In the past decade the molecular basis of many inherited syndromes has been unravelled. This article reviews the clinical and genetic aspects of inherited syndromes that are characterised by skin appendage neoplasms, including Cowden syndrome, Birt–Hogg–Dube syndrome, naevoid basal cell carcinoma syndrome, generalised basaloid follicular hamartoma syndrome, Bazex syndrome, Brooke–Spiegler syndrome, familial cylindromatosis, multiple familial trichoepitheliomas, and Muir–Torre syndrome.


Journal of Medical Genetics | 1999

Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN

Julide Tok Celebi; Hui C. Tsou; Fei Fei Chen; Hong Zhang; Xiao Li Ping; Mark G Lebwohl; Jeffrey Kezis; Monica Peacocke

Cowden syndrome (CS) and Bannayan-Zonana syndrome (BZS) are two hamartoma syndromes with distinct phenotypic features. Although partial clinical overlap exists between CS and BZS, they are considered to be separate entities. PTEN has been identified as the susceptibility gene for both disorders, suggesting allelism. We have identified a germline mutation, R335X, in PTEN in a family consisting of two female members with the phenotypic findings of CS and two male members with the phenotypic findings of BZS. To our knowledge, this is the first report that shows the presence of separate subjects with CS and with BZS in a single family associated with a single germline PTEN mutation.


American Journal of Pathology | 2009

Gab2-Mediated Signaling Promotes Melanoma Metastasis

Basil Horst; Sofia K. Gruvberger-Saal; Benjamin D. Hopkins; Lindsey Bordone; Ying Yang; Karen A. Chernoff; Ijeoma Uzoma; Volker Schwipper; Jutta Liebau; Norma J. Nowak; Georg Brunner; David F. Owens; David L. Rimm; Ramon Parsons; Julide Tok Celebi

Metastatic melanoma is a disease with a poor prognosis that currently lacks effective treatments. Critical biological features of metastasis include acquisition of migratory competence, growth factor independence, and invasive potential. In an attempt to identify genes that contribute to melanoma pathogenesis, a genome-wide search using bacterial artificial chromosome array comparative genomic hybridization and single nucleotide polymorphism arrays in a series of 64 metastatic melanoma samples and 20 melanoma cell lines identified increased copy numbers of Gab2 located on 11q14.1. Gab2 is an adaptor protein that potentiates the activation of the Ras-Erk and PI3K-Akt pathways and has recently been implicated in human cancer; however, its role in melanoma has not been explored. In this study, we found that Gab2 was either amplified (approximately 11%) and/or overexpressed (approximately 50%) in melanoma. Gab2 protein expression correlated with clinical melanoma progression, and higher levels of expression were seen in metastatic melanomas compared with primary melanoma and melanocytic nevi. We found that overexpression of Gab2 potentiates, whereas silencing of Gab2 reduces, migration and invasion of melanoma cells. Gab2 mediated the hyperactivation of Akt signaling in the absence of growth factors, whereas inhibition of the PI3K-Akt pathway decreased Gab2-mediated tumor cell migration and invasive potential. Gab2 overexpression resulted in enhanced tumor growth and metastatic potential in vivo. These studies demonstrate a previously undefined role for Gab2 in melanoma tumor progression and metastasis.


Cancer | 2007

Influence of age on survival in childhood spitzoid melanomas.

Marlyanne Pol‐Rodriquez; Shing Lee; David N. Silvers; Julide Tok Celebi

Melanoma occurring during childhood and adolescence is rare. Although a few limited studies suggest that the prognosis of childhood melanomas is similar to those in adults, and is dependent on the initial stage of the tumor, there is controversy with respect to the biologic behavior of childhood melanomas. Spitzoid melanoma is a subtype of melanoma with distinct clinical and histopathologic features. The prognosis of spitzoid melanoma in children, despite metastasis, has been suggested to be better than that observed in adults; however, this assertion remains controversial. Whereas a number of spitzoid melanomas with regional lymph node metastasis with no further progression have been reported, cases leading to widespread metastasis and fatal outcomes are also well documented.


Clinical Cancer Research | 2009

GAB2 Amplifications Refine Molecular Classification of Melanoma

Karen A. Chernoff; Lindsey Bordone; Basil A. Horst; Katherine Simon; William Twadell; Keagan Lee; Jason A. Cohen; Shuang Wang; David N. Silvers; Georg Brunner; Julide Tok Celebi

Purpose: Gain-of-function mutations in BRAF, NRAS, or KIT are associated with distinct melanoma subtypes with KIT mutations and/or copy number changes frequently observed among melanomas arising from sun-protected sites, such as acral skin (palms, soles, and nail bed) and mucous membranes. GAB2 has recently been implicated in melanoma pathogenesis, and increased copy numbers are found in a subset of melanomas. We sought to determine the association of increased copy numbers of GAB2 among melanoma subtypes in the context of genetic alterations in BRAF, NRAS, and KIT. Experimental Design: A total of 85 melanomas arising from sun-protected (n = 23) and sun-exposed sites (n = 62) were analyzed for copy number changes using array-based comparative genomic hybridization and for gain-of-function mutations in BRAF, NRAS, and KIT. Results:GAB2 amplifications were found in 9% of the cases and were associated with melanomas arising from acral and mucosal sites (P = 0.005). Increased copy numbers of the KIT locus were observed in 6% of the cases. The overall mutation frequencies for BRAF and NRAS were 43.5% and 14%, respectively, and were mutually exclusive. Among the acral and mucosal melanomas studied, the genetic alteration frequency was 26% for GAB2, 13% for KIT, 30% for BRAF, and 4% for NRAS. Importantly, the majority of GAB2 amplifications occurred independent from genetic events in BRAF, NRAS, and KIT. Conclusions:GAB2 amplification is critical for melanomas arising from sun-protected sites. Genetic alterations in GAB2 will help refine the molecular classification of melanomas.


Clinical Cancer Research | 2009

Association of MDM2 SNP309, Age of Onset, and Gender in Cutaneous Melanoma

Elnaz F. Firoz; Melanie Warycha; Jan Zakrzewski; Danuta Pollens; Guimin Wang; Richard L. Shapiro; Russell S. Berman; Anna C. Pavlick; Prashiela Manga; Harry Ostrer; Julide Tok Celebi; Hideko Kamino; Farbod Darvishian; Linda Rolnitzky; Judith D. Goldberg; Iman Osman; David Polsky

Purpose: In certain cancers, MDM2 SNP309 has been associated with early tumor onset in women. In melanoma, incidence rates are higher in women than in men among individuals less than 40 years of age, but among those older than 50 years of age, melanoma is more frequent in men than in women. To investigate this difference, we examined the association among MDM2 SNP309, age at diagnosis, and gender among melanoma patients. Experimental Design: Prospectively enrolled melanoma patients (N = 227) were evaluated for MDM2 SNP309 and the related polymorphism, p53 Arg72Pro. DNA was isolated from patient blood samples, and genotypes were analyzed by PCR-restriction fragment length polymorphism. Associations among MDM2 SNP309, p53 Arg72Pro, age at diagnosis, and clinicopathologic features of melanoma were analyzed. Results: The median age at diagnosis was 13 years earlier among women with a SNP309 GG genotype (46 years) compared with women with TG+TT genotypes (59 years; P = 0.19). Analyses using age dichotomized at each decade indicated that women with a GG genotype had significantly higher risks of being diagnosed with melanoma at ages <50 years compared with women ≥50 years, but not when the comparison was made between women <60 and ≥60 years. At ages <50 years, women with a GG genotype had a 3.89 times greater chance of being diagnosed compared with women with TG+TT genotypes (P = 0.01). Similar observations were not seen among men. Conclusions: Our data suggest that MDM2 may play an important role in the development of melanoma in women. The MDM2 SNP309 genotype may help identify women at risk of developing melanoma at a young age.


Clinical and Experimental Dermatology | 2003

Identification of a recurrent mutation in the CYLD gene in Brooke-Spiegler syndrome.

N. Scheinfeld; Guofang Hu; Melissa Gill; C. Austin; Julide Tok Celebi

Summary Brooke–Spiegler syndrome is an autosomal dominantly inherited disease with predisposition to neoplasms of the skin appendages. The disease has been mapped to 16q, and mutations in the CYLD gene have been identified in families with this disorder. We describe an individual with BSS exhibiting clinical heterogeneity in which a heterozygous frameshift mutation in CYLD, 2172delA, has been identified. These findings extend the body of evidence that mutations in CYLD are involved in Brooke‐Spiegler syndrome and provide additional information for phenotype–genotype correlation.


Human Genetics | 2000

Association of splicing defects in PTEN leading to exon skipping or partial intron retention in Cowden syndrome.

Julide Tok Celebi; Molly Wanner; Xiao Li Ping; Hong Zhang; Monica Peacocke

Abstract. Cowden syndrome (CS) and Bannayan Zonana syndrome (BZS) are two autosomal dominantly inherited conditions characterized by hamartomas. Mutations in PTEN, a tumor suppressor gene located on chromosome 10q23, have been identified in patients with phenotypic findings of both CS and BZS. These mutations are found throughout the entire gene, with exon 5 being the most common site, and include point mutations, insertions and deletions. To date, 11 point mutations at the splice junctions of the PTEN gene have been reported, however, data on the alterations in the transcripts have been lacking. In this study, we have identified three novel splice site mutations in PTEN, in two families with CS and in one individual with BZS. One mutation affected the splice-acceptor site, which resulted in out-of-frame skipping of an entire exon. By contrast, the other two mutations affected the splice-donor sites, and both showed inclusion of partial intronic sequences in the transcript due to activation of cryptic splice sites. These data demonstrate mRNA alterations as a consequence of splice site mutations in the PTEN gene.

Collaboration


Dive into the Julide Tok Celebi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Iraz T. Aydin

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brateil Badal

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Franco Abbate

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Geena Susan Rajan

Icahn School of Medicine at Mount Sinai

View shared research outputs
Researchain Logo
Decentralizing Knowledge